Greenwich Lifesciences, Inc. : H.c. Wainwright Raises Target Price to $50 From $39

BRIEF-Propanc Biopharma Files Prospectus For Resale Of 2 Million Shares By Selling Stockholder - SEC Filing

Entera Bio CEO Miranda Jayne Toledano Reports Acquisition of Common Shares

BRIEF-Medicus Pharma To Offer Securities Worth Up To $100 Million - SEC Filing

Propanc Biopharma Inc - Files Prospectus for Resale of 2 Mln Shares by Selling Stockholder - SEC Filing

Lite Strategy Inc. Grants CEO Justin J. File New Employment Agreement with Enhanced Severance Benefits

Medicus Pharma Ltd - to Offer Securities Worth up to $100 Mln - SEC Filing

U.S. RESEARCH ROUNDUP-Citigroup, DigitalBridge, Verisk Analytics

Mesoblast to Release 10.2 Million Shares From Voluntary Escrow

BUZZ-India's Orient Technologies rises after shareholders approve bonus issue

Mereo Biopharma Group Plc : Leerink Partners Cuts Target Price to $2 From $8

Ultragenyx Pharmaceutical Inc : Piper Sandler Cuts Target Price to $75 From $105

Director Cyrus Harmon Reports Sale of Olema Pharmaceuticals Common Shares

Junce Bio Focuses on "Lymphodepletion-Free" Breakthrough in Solid Tumors, GC101 Expected to Submit Marketing Application in 2026

Travere Therapeutics Chief Medical Officer Jula Inrig Reports Disposal of Common Shares

Roivant Sciences CFO Richard Pulik Reports Disposal of Common Shares

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Travere Therapeutics SVP and Chief Accounting Officer Sandra Calvin Reports Sale of Common Shares

OrbiMed Advisors Reports Disposal of Sionna Therapeutics Inc. Common Shares